Renaissance Group LLC purchased a new position in Horizon Pharma PLC (NASDAQ:HZNP) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 16,253 shares of the biopharmaceutical company’s stock, valued at approximately $263,000.
Other hedge funds have also modified their holdings of the company. Quantbot Technologies LP acquired a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $112,000. HL Financial Services LLC acquired a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $196,000. Fort Point Capital Partners LLC acquired a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $245,000. M&T Bank Corp acquired a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $273,000. Finally, Gradient Investments LLC acquired a new stake in shares of Horizon Pharma PLC during the third quarter worth approximately $288,000. Institutional investors and hedge funds own 88.09% of the company’s stock.
Shares of Horizon Pharma PLC (NASDAQ:HZNP) remained flat at $17.02 during mid-day trading on Friday. 622,301 shares of the company’s stock traded hands. The stock’s market cap is $2.74 billion. The firm has a 50-day moving average price of $16.78 and a 200 day moving average price of $18.40. Horizon Pharma PLC has a 52-week low of $13.05 and a 52-week high of $23.44.
This story was first published by WKRB News and is the sole property of of WKRB News. If you are reading this story on another website, it was illegally copied and republished in violation of U.S. and international copyright law. The original version of this story can be read at http://www.wkrb13.com/markets/1981540/renaissance-group-llc-takes-position-in-horizon-pharma-plc-hznp.html.
A number of brokerages recently commented on HZNP. Jefferies Group LLC set a $26.00 price target on Horizon Pharma PLC and gave the stock a “buy” rating in a report on Thursday, December 8th. Zacks Investment Research lowered Horizon Pharma PLC from a “hold” rating to a “strong sell” rating in a report on Tuesday, November 29th. Mizuho lifted their price target on Horizon Pharma PLC from $29.00 to $30.00 and gave the stock a “buy” rating in a report on Tuesday, November 8th. BMO Capital Markets reiterated an “outperform” rating and set a $24.00 price target (down from $29.00) on shares of Horizon Pharma PLC in a report on Thursday, December 8th. Finally, Citigroup Inc. upgraded Horizon Pharma PLC from a “neutral” rating to a “buy” rating in a research note on Monday, November 28th. One analyst has rated the stock with a sell rating, two have given a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Horizon Pharma PLC has an average rating of “Buy” and an average price target of $28.77.
Horizon Pharma PLC Company Profile
Horizon Pharma plc, formerly Vidara Therapeutics International Public Limited Company, is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring or in-licensing and commercializing differentiated products. It markets approximately nine medicines through its orphan, primary care and rheumatology business units.
Want to see what other hedge funds are holding HZNP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Horizon Pharma PLC (NASDAQ:HZNP).
This story was originally published by WKRB News (http://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at http://www.wkrb13.com/markets/1981540/renaissance-group-llc-takes-position-in-horizon-pharma-plc-hznp.html
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.